Literature DB >> 23584515

Using pretreatment tumor depth and length to select esophageal squamous cell carcinoma patients for nonoperative treatment after neoadjuvant chemoradiotherapy.

Yin-Kai Chao1, Chen-Kan Tseng, Yu-Wen Wen, Yun-Hen Liu, Yung-Liang Wan, Cheng-Tung Chiu, Wen-Cheng Chang, Hsien-Kun Chang.   

Abstract

BACKGROUND: Two randomized trials have shown that in patients with good response to neoadjuvant chemoradiotherapy (nCRT), a nonoperative approach (additional CRT) had equal survival to scheduled esophagectomy. However, controversy exists because of the high locoregional recurrence (LR) following a nonoperative approach. Endoscopic complete response (e-CR) determined by endoscopic finding is a good criterion for predicting local control after definitive CRT. We evaluated whether e-CR could also be used to select patients for nonoperative treatment after nCRT.
METHODS: We retrospectively analyzed esophageal squamous cell carcinoma (SCC) patients with e-CR after nCRT between 1999 and 2006. Patients were divided into two groups by the type of treatment given after e-CR (group A, scheduled esophagectomy; group B, no scheduled surgery and continued CRT).
RESULTS: There were 71 and 79 patients in groups A and B, respectively with similar pre/post-nCRT characteristics. Despite similarity in survival and recurrence between groups, the recurrence site differed significantly. LR occurred more frequently in group B, whereas systemic recurrence was the predominant failure pattern in group A (P<.001). With use of multivariate analysis on group B, we determined that pretreatment depth of tumor invasion≥T3 [odds ratio (OR), 11.19; 95% CI, 1.4-89; unfavorable, P=.023] and tumor length≥6 cm (OR, 3.069; 95% CI, 1.17-8.1; unfavorable, P=.023) were predictors for LR. Patients with initial clinical T2 and <6 cm tumor had comparable LR (5%) to the surgery group; these patients were candidates for nonoperative treatment after nCRT.
CONCLUSION: In esophageal SCC patients who achieved e-CR after nCRT, pretreatment tumor depth and length were good indicators to select candidates for nonoperative treatment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23584515     DOI: 10.1245/s10434-013-2962-1

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  9 in total

Review 1.  Clinical tools to predict outcomes in patients with esophageal cancer treated with definitive chemoradiation: are we there yet?

Authors:  Abraham J Wu; Karyn A Goodman
Journal:  J Gastrointest Oncol       Date:  2015-02

2.  A prognostic nomogram for overall survival after neoadjuvant radiotherapy or chemoradiotherapy in thoracic esophageal squamous cell carcinoma: a retrospective analysis.

Authors:  Wei Deng; Qifeng Wang; Zefen Xiao; Lijun Tan; Zhao Yang; Zongmei Zhou; Hongxing Zhang; Dongfu Chen; Qinfu Feng; Jun Liang; Yexiong Li; Jie He; Shugeng Gao; Kelin Sun; Guiyu Cheng; Xiangyang Liu; Dekang Fang; Qi Xue; Yousheng Mao; Dali Wang; Jian Li
Journal:  Oncotarget       Date:  2017-06-20

3.  GALNT14 genotype as a response predictor for concurrent chemoradiotherapy in advanced esophageal squamous cell carcinoma.

Authors:  Yung-Kuan Tsou; Kung-Hao Liang; Wey-Ran Lin; Hsien-Kun Chang; Chen-Kan Tseng; Chau-Ting Yeh
Journal:  Oncotarget       Date:  2017-04-25

4.  Clinical complete response after chemoradiotherapy for carcinoma of thoracic esophagus: Is esophagectomy always necessary? A systematic review and meta-analysis.

Authors:  Jun Wang; Jianjun Qin; Shaowu Jing; Qing Liu; Yunjie Cheng; Yi Wang; Feng Cao
Journal:  Thorac Cancer       Date:  2018-10-01       Impact factor: 3.500

5.  MED15, transforming growth factor beta 1 (TGF-β1), FcγRIII (CD16), and HNK-1 (CD57) are prognostic biomarkers of oral squamous cell carcinoma.

Authors:  Maryam Elahi; Vahid Rakhshan
Journal:  Sci Rep       Date:  2020-05-21       Impact factor: 4.379

6.  Omitting surgery in esophageal cancer patients with complete response after neoadjuvant chemoradiotherapy: a systematic review and meta-analysis.

Authors:  Jaehyeon Park; Ji Woon Yea; Se An Oh; Jae Won Park
Journal:  Radiat Oncol       Date:  2021-11-14       Impact factor: 3.481

7.  Could 18-FDG PET-CT Radiomic Features Predict the Locoregional Progression-Free Survival in Inoperable or Unresectable Oesophageal Cancer?

Authors:  Berardino De Bari; Loriane Lefevre; Julie Henriques; Roberto Gatta; Antoine Falcoz; Pierre Mathieu; Christophe Borg; Nicola Dinapoli; Hatem Boulahdour; Luca Boldrini; Vincenzo Valentini; Dewi Vernerey
Journal:  Cancers (Basel)       Date:  2022-08-22       Impact factor: 6.575

8.  Distribution of Peripheral Blood Cells in Esophageal Cancer Patients During Concurrent Chemoradiotherapy Predicts Long-Term Locoregional Progression Hazard After Treatment (GASTO1072).

Authors:  Liangyu Xu; Jianzhou Chen; Hong Guo; Ruihong Huang; Longjia Guo; Yuanxiang Yu; Tiantian Zhai; Fangcai Wu; Zhijian Chen; Derui Li; Chuangzhen Chen
Journal:  Cancer Manag Res       Date:  2021-05-25       Impact factor: 3.989

9.  Does tumor size improve the accuracy of prognostic prediction in patients with esophageal squamous cell carcinoma after surgical resection?

Authors:  Hongdian Zhang; Peng Tang; Xiaohui Miao; Yongyin Gao; Xiaobin Shang; Lei Gong; Zhao Ma; Mingjian Yang; Hongjing Jiang; Zhongli Zhan; Bin Meng; Zhentao Yu
Journal:  Oncotarget       Date:  2016-10-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.